TWST - NASDAQ

Twist Bioscience Corporation

Twist Bioscience Corporation

TWSTยทNASDAQ

$72.33

+0.41%
HealthcareMedical - Diagnostics & Research

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$4.50B
EPS-1.3000
P/E Ratio-55.64
Earnings Date08/03/2026
Twist Bioscience Corporation

Twist Bioscience Corporation Fair Value Envelope

TWST ยท NASDAQ

Our analysis suggests that TWST has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $72.33, this represents a potential HIDDEN relative to our calculated worth for Twist Bioscience Corporation.

HIDDEN
Intrinsic Value
Current Price: $72.33

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$229.9M
+ Cash & Equivalents$183.0M
Firm Value-$46.9M
- Debt$137.3M
Equity Value-$184.2M
/ Shares Outstanding60,360,925B
DCF Value-$3
OVERVALUED BY 104%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$43.2M
-$39.1M
-$35.5M
-$32.2M
-$29.2M
-$26.4M
-$24.0M
-$21.7M
-$19.7M
-$17.9M
Maintenance CapEx
-$5.1M
-$4.6M
-$4.2M
-$3.8M
-$3.4M
-$3.1M
-$2.8M
-$2.6M
-$2.3M
-$2.1M
Owner Earnings
-$48.3M
-$43.7M
-$39.7M
-$36.0M
-$32.6M
-$29.6M
-$26.8M
-$24.3M
-$22.0M
-$20.0M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$44.7M
-$37.5M
-$31.5M
-$26.4M
-$22.2M
-$18.6M
-$15.6M
-$13.1M
-$11.0M
-$9.2M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TWST research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.